SeaStar Medical Holding Corp
ICU Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2021โFY2025
Last close ยท Oct 23, 2026
$2.41
15.4%
Revenue
Total sales reported in the income statement.
$1.2M
814.1%
vs prior year
Operating margin
Operating income as a share of revenue.
โ986.6%
12,229.7ย pts
Net income
Profit after all expenses, interest and tax.
โ$12.2M
Free cash flow
Cash from operations minus capital spending.
โ
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
What SeaStar Medical Holding Corp does
No business description yet.
- Legal name
- SeaStar Medical Holding Corp
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 25, 2026
- Accession ยท CIK
- 0001437749-26-009797
0001831868
Revenue and margins
SeaStar Medical Holding Corp had $1.2M of revenue in fiscal 2025, up 814.1% on the year before.
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue $0.0M
FY24
Revenue $0.1M
FY25
Revenue $1.2M
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $0.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.1M
Q4 '24
Revenue $0.1M
Q1 '25
Revenue $0.3M
Q2 '25
Revenue $0.3M
Q3 '25
Revenue $0.2M
Q4 '25
Revenue $0.4M
Q1 '26
Revenue $0.5M
Q2 '26
Revenue $0.6M
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross 100.0%
Operating โ13,216.3%
Net โ18,392.6%
FCF โ
FY25
Gross 95.7%
Operating โ986.6%
Net โ984.6%
FCF โ
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ
Net โ
FCF โ
Q4 '23
Gross โ
Operating โ
Net โ
FCF โ
Q1 '24
Gross โ
Operating โ
Net โ
FCF โ
Q2 '24
Gross โ
Operating โ
Net โ
FCF โ
Q3 '24
Gross 100.0%
Operating โ6,552.9%
Net โ6,585.3%
FCF โ
Q4 '24
Gross 100.0%
Operating โ7,114.9%
Net โ6,595.5%
FCF โ
Q1 '25
Gross 100.0%
Operating โ1,304.4%
Net โ1,287.4%
FCF โ
Q2 '25
Gross 92.0%
Operating โ519.5%
Net โ592.3%
FCF โ
Q3 '25
Gross 92.3%
Operating โ1,955.7%
Net โ1,897.3%
FCF โ
Q4 '25
Gross 97.1%
Operating โ718.1%
Net โ691.4%
FCF โ
Q1 '26
Gross 90.7%
Operating โ727.9%
Net โ711.3%
FCF โ
Q2 '26
Gross 91.2%
Operating โ616.4%
Net โ606.5%
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY21
Net income โ$4.6M
FY22
Net income โ$12.2M
FY23
Net income โ$26.2M
FY24
Net income โ$24.8M
FY25
Net income โ$12.2M
Q3 '23
Net income โ$7.2M
Q4 '23
Net income โ$9.5M
Q1 '24
Net income โ$12.7M
Q2 '24
Net income โ$3.2M
Q3 '24
Net income โ$4.5M
Q4 '24
Net income โ$4.4M
Q1 '25
Net income โ$3.8M
Q2 '25
Net income โ$2.0M
Q3 '25
Net income โ$3.5M
Q4 '25
Net income โ$2.9M
Q1 '26
Net income โ$3.5M
Q2 '26
Net income โ$3.7M
FY21
Diluted EPS โ$0.63
FY22
Diluted EPS โ$1.48
FY23
Diluted EPS โ$30.26
FY24
Diluted EPS โ$6.63
FY25
Diluted EPS โ
Q3 '23
Diluted EPS โ$9.02
Q4 '23
Diluted EPS โ$16.60
Q1 '24
Diluted EPS โ$4.73
Q2 '24
Diluted EPS โ$1.03
Q3 '24
Diluted EPS โ$1.10
Q4 '24
Diluted EPS $0.23
Q1 '25
Diluted EPS โ$0.44
Q2 '25
Diluted EPS โ$0.18
Q3 '25
Diluted EPS โ
Q4 '25
Diluted EPS โ
Q1 '26
Diluted EPS โ
Q2 '26
Diluted EPS โ
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY21
Return on capital โ
Return on equity โ
Return on assets โ762.2%
FY22
Return on capital โ
Return on equity โ
Return on assets โ669.6%
FY23
Return on capital โ
Return on equity โ
Return on assets โ800.9%
FY24
Return on capital โ
Return on equity โ
Return on assets โ607.8%
FY25
Return on capital โ
Return on equity โ295.2%
Return on assets โ129.1%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY21
Free cash flow โ
FY22
Free cash flow โ
FY23
Free cash flow โ
FY24
Free cash flow โ
FY25
Free cash flow โ
FY21
Cash from operations โ$5.1M
Capital spending โ
FY22
Cash from operations โ$7.8M
Capital spending โ
FY23
Cash from operations โ$10.3M
Capital spending โ
FY24
Cash from operations โ$16.0M
Capital spending โ
FY25
Cash from operations โ$13.6M
Capital spending โ
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$1.3M
Capital spending โ
Q4 '23
Cash from operations โ$4.5M
Capital spending โ
Q1 '24
Cash from operations โ$3.5M
Capital spending โ
Q2 '24
Cash from operations โ$2.8M
Capital spending โ
Q3 '24
Cash from operations โ$5.0M
Capital spending โ
Q4 '24
Cash from operations โ$4.7M
Capital spending โ
Q1 '25
Cash from operations โ$2.7M
Capital spending โ
Q2 '25
Cash from operations โ$3.0M
Capital spending โ
Q3 '25
Cash from operations โ$3.8M
Capital spending โ
Q4 '25
Cash from operations โ$4.1M
Capital spending โ
Q1 '26
Cash from operations โ$2.8M
Capital spending โ
Q2 '26
Cash from operations โ$3.0M
Capital spending โ
Cash from operations
Capital spending
Dividends, buybacks and share count
SeaStar Medical Holding Corp returned โ to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY21
Diluted shares 0.01B
FY22
Diluted shares 0.01B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares โ
Balance sheet
Cash, debt and the ratios that show how comfortably SeaStar Medical Holding Corp can carry it.
FY21
Cash $0.1M
Debt โ
FY22
Cash $0.0M
Debt $7.7M
FY23
Cash $0.2M
Debt $4.1M
FY24
Cash $1.8M
Debt $0.6M
FY25
Cash $12.0M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.1M | $0.0M | $0.2M | $1.8M | $12.0M |
| Debt incl. finance leases | โ | $7.7M | $4.1M | $0.6M | โ |
| Interest coverage | โ21.0x | โ18.4x | โ13.1x | โ73.1x | โ392.7x |
| Current ratio | 0.2x | 0.1x | 0.2x | 0.6x | 3.6x |
| Quick ratio | 0.2x | 0.1x | 0.2x | 0.6x | 3.6x |
| Total assets | $0.6M | $3.0M | $3.5M | $4.7M | $14.2M |
| Total liabilities | $3.4M | $23.8M | $17.4M | $6.8M | $3.7M |
| Shareholders' equity | โ$2.8M | โ$20.8M | โ$13.9M | โ$2.2M | $10.4M |
| Net debt (โ = net cash) | โ | $7.6M | $4.0M | โ$1.2M | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | 4 / 7 | 5 / 8 | 3 / 7 |
| Accruals ratio | 85.9% | โ241.5% | โ486.9% | โ216.0% | 15.4% |
| Altman Z'' | โ490.42 | โ153.15 | โ154.54 | โ128.08 | โ33.23 |
5 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | โ | โ | $0.0M | $0.1M | $1.2M |
| Gross profit | โ | โ | $0.0M | $0.1M | $1.2M |
| Research and development | $2.8M | $2.5M | $6.0M | $9.1M | $7.5M |
| Operating income | โ$4.4M | โ$11.6M | โ$14.2M | โ$17.8M | โ$12.2M |
| Interest expense | $0.2M | $0.6M | $1.1M | $0.2M | $0.0M |
| Pretax income | โ$4.6M | โ$12.2M | โ$26.2M | โ$24.8M | โ$12.1M |
| Income tax | โ$0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | โ$4.6M | โ$12.2M | โ$26.2M | โ$24.8M | โ$12.2M |
| Diluted EPS | โ$0.63 | โ$1.48 | โ$30.26 | โ$6.63 | โ |
| Diluted shares | 0.01B | 0.01B | 0.00B | 0.00B | โ |
| Cash flow | |||||
| Cash from operations | โ$5.1M | โ$7.8M | โ$10.3M | โ$16.0M | โ$13.6M |
| Stock-based compensation | $0.0M | $1.3M | $1.9M | $0.9M | $0.6M |
| Balance sheet | |||||
| Cash and short-term investments | $0.1M | $0.0M | $0.2M | $1.8M | $12.0M |
| Total debt | โ | $7.7M | $4.1M | $0.6M | โ |
| Current assets | $0.6M | $1.5M | $2.3M | $3.8M | $13.6M |
| Current liabilities | $3.1M | $16.1M | $13.0M | $6.8M | $3.7M |
| Inventory | โ | โ | โ | $0.0M | $0.1M |
| Total assets | $0.6M | $3.0M | $3.5M | $4.7M | $14.2M |
| Total liabilities | $3.4M | $23.8M | $17.4M | $6.8M | $3.7M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | โ$2.8M | โ$20.8M | โ$13.9M | โ$2.2M | $10.4M |
| Margins | |||||
| Gross margin | โ | โ | โ | 100.0% | 95.7% |
| Operating margin | โ | โ | โ | โ13,216.3% | โ986.6% |
| Net margin | โ | โ | โ | โ18,392.6% | โ984.6% |
| Returns | |||||
| Return on capital employed | 176.8% | 88.6% | 149.1% | 817.3% | โ116.9% |
| Return on equity | โ | โ | โ | โ | โ295.2% |
| Return on assets | โ762.2% | โ669.6% | โ800.9% | โ607.8% | โ129.1% |
| Return on tangible equity | โ | โ | โ | โ | โ116.6% |
| Growth | |||||
| Revenue growth | โ | โ | โ | โ | 814.1% |
| Share count change | โ | 13.4% | โ89.4% | 331.9% | โ |
| Financial health | |||||
| Interest coverage | โ21.0x | โ18.4x | โ13.1x | โ73.1x | โ392.7x |
| Current ratio | 0.2x | 0.1x | 0.2x | 0.6x | 3.6x |
| Quick ratio | 0.2x | 0.1x | 0.2x | 0.6x | 3.6x |
| Capital allocation | |||||
| Stock comp / revenue | โ | โ | โ | 657.0% | 50.6% |
| Quality scores | |||||
| Piotroski F-score | โ | โ | 4.0 | 5.0 | 3.0 |
| Altman Z'' | โ490.4 | โ153.2 | โ154.5 | โ128.1 | โ33.2 |
| Accruals ratio | 85.9% | โ241.5% | โ486.9% | โ216.0% | 15.4% |
Source: SEC EDGAR XBRL filings (CIK 0001831868). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.